Anxiolytic effects of the flavonoid luteolin in a mouse model of acute colitis

dc.contributor.authorGadotti, Vinicius M
dc.contributor.authorZamponi, Gerald W
dc.date.accessioned2019-12-29T01:05:36Z
dc.date.available2019-12-29T01:05:36Z
dc.date.issued2019-12-26
dc.date.updated2019-12-29T01:05:35Z
dc.description.abstractAbstract Anxiety related disorders commonly occur in association with major depressive disorder (MDD) in individuals suffering from peripheral inflammation, with a higher prevalence among IBS patients. We have previously shown that the bioflavonoid luteolin has pronounced analgesic and antidepressant-like effects in mice with dextran sodium sulfate (DSS)-induced colitis. Here, we further evaluate the biological effect of luteolin as a possible anxiolytic agent in DSS treated mice. Anxiolytic action was evaluated using the open field test (OF), the novelty suppressed feeding test (NSFT) and the elevated plus maze test (EPM). Luteolin increased the number of crossings in the center of the OF apparatus, reduced the latency to interact with the food pellet in the NSFT, and increased the time spent in the open arms in the EPM. These results suggest luteolin as a possible natural anxiolytic molecule without sedative effects, thus reinforcing its therapeutic potential for the comorbidities involving peripheral inflammation, pain, mood and anxiety-related disorders.
dc.identifier.citationMolecular Brain. 2019 Dec 26;12(1):114
dc.identifier.doihttps://doi.org/10.1186/s13041-019-0539-z
dc.identifier.urihttp://hdl.handle.net/1880/111397
dc.identifier.urihttps://doi.org/10.11575/PRISM/43966
dc.language.rfc3066en
dc.rights.holderThe Author(s).
dc.titleAnxiolytic effects of the flavonoid luteolin in a mouse model of acute colitis
dc.typeunknown
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
13041_2019_Article_539.pdf
Size:
429.79 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description: